Diabetic Drug May Reduce Cardiovascular Mortality
Drugs developed for the treatment of Type 2 diabetes may benefit patients with heart failure (HF), as per a new study from Harvard-affiliated Brigham and Women’s Hospital.
The scientists presented research from the largest trial to date of heart failure patients with mildly reduced or preserved ejection fraction. (Ejection fraction is a measurement of how much blood is ejected from the heart as it contracts.) The study was published in The New England Journal of Medicine and The Lancet.
Researchers found that dapagliflozin, which had previously been shown to benefit patients with heart failure with reduced ejection fraction, is likely to also reduce cardiovascular deaths and hospitalization for patients with mildly reduced or preserved ejection fraction.
Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor, a class of drugs that causes the body to excrete sugar in urine. In addition to controlling blood sugar in patients with diabetes, SGLT-2 inhibitors have been shown to provide significant cardiovascular and kidney disease benefits.
These findings establish SGLT2 inhibitors as foundational treatment for patients living with heart failure, regardless of ejection fraction, to help prevent hospitalization and morbidity and to extend meaningful survival and improve health-related quality of life.
All About COVID-19 For Your Patients
WhiteCoats Insights For Your Practice
Join Thousands of Doctors who Trust WhiteCoats as their Professional Success Partner
For more queries, Call +91-7406-485-000 or mail us at sales@whitecoats.com
Download our App
